DJIA 18,053.71 23.50 0.13%
NASDAQ 4,806.86 33.39 0.70%
S&P 500 2,088.77 6.89 0.33%
market minute promo

Allergan, Inc. (NYSE: AGN)



company name or ticker
Company Photos
(Click to zoom)

Goldman's Parker Calls Allergan Pursuit a 'One-time Opportunity'

Sanofi's Priftin Gains U.S. Approval for Latent TB Indication - Analyst Blog

Why the Allergan Situation Could be Unique in Dealmaking This Year

Gilead Sciences: An Alpha Stock Through The Good And Bad Times

Consumer Health Spending a Welcome Wrinkle for Allergan-Actavis Deal

With consumer spending on "descrtionary items" like elective healthcare procedures, treatments and products on the rise, the combined Actavis and Allergan with its portfolio of cosmetic drugs like Botox will benefit.

AstraZeneca's (AZN) Iressa Accepted for Review in the U.S. - Analyst Blog

Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now

#PreMarket Primer: Wednesday, December 3: Investors Weigh The Possibility Of More Easing In The Euro

#PreMarket Primer: Wednesday, December 3: Investors Weigh The Possibility Of More Easing In The Eurozone

Actavis Launches Generic of Shire's ADHD Drug Intuniv - Analyst Blog

Novartis' Multiple Sclerosis Drug Gilenya Fails Phase III Study - Analyst Blog

See More Articles...